Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Fenofibrate and losartan.

Literature DB >> 12759281

Fenofibrate and losartan.

T Bardin¹.

Abstract

Entities: Chemical

Mesh：

Substances：

Year: 2003 PMID： 12759281 PMCID： PMC1754575 DOI： 10.1136/ard.62.6.497

Source DB: PubMed Journal: Ann Rheum Dis ISSN： 0003-4967 Impact factor: 19.103

× No keyword cloud information.

28 in total

1. Effect of angiotensin and norepinephrine upon urate clearance in man.

Authors: T F Ferris; P Gorden
Journal: Am J Med Date: 1968-03 Impact factor: 4.965

2. Safety of losartan in hypertensive patients with thiazide-induced hyperuricemia.

Authors: S Shahinfar; R L Simpson; A D Carides; B Thiyagarajan; Y Nakagawa; J G Umans; J H Parks; F L Coe
Journal: Kidney Int Date: 1999-11 Impact factor: 10.612

3. Effect of eprosartan and losartan on uric acid metabolism in patients with essential hypertension.

Authors: J G Puig; F Mateos; A Buño; R Ortega; F Rodriguez; R Dal-Ré
Journal: J Hypertens Date: 1999-07 Impact factor: 4.844

4. Molecular identification of a renal urate anion exchanger that regulates blood urate levels.

Authors: Atsushi Enomoto; Hiroaki Kimura; Arthit Chairoungdua; Yasuhiro Shigeta; Promsuk Jutabha; Seok Ho Cha; Makoto Hosoyamada; Michio Takeda; Takashi Sekine; Takashi Igarashi; Hirotaka Matsuo; Yuichi Kikuchi; Takashi Oda; Kimiyoshi Ichida; Tatsuo Hosoya; Kaoru Shimokata; Toshimitsu Niwa; Yoshikatsu Kanai; Hitoshi Endou
Journal: Nature Date: 2002-04-14 Impact factor: 49.962

5. Hypolipidemic and hypouricemic action of fenofibrate in various types of hyperlipoproteinemias.

Authors: C Harvengt; F Heller; J P Desager
Journal: Artery Date: 1980

6. Uricosuric effect of fenofibrate in healthy volunteers.

Authors: J P Desager; R Hulhoven; C Harvengt
Journal: J Clin Pharmacol Date: 1980-10 Impact factor: 3.126

7. Asymptomatic hyperuricemia: the case for conservative management.

Authors: M H Liang; J F Fries
Journal: Ann Intern Med Date: 1978-05 Impact factor: 25.391

8. Evaluation of renal handling of uric acid in essential hypertension: hyperuricemia related to decreased urate secretion.

Authors: A Tykarski
Journal: Nephron Date: 1991 Impact factor: 2.847

9. Hypertriglyceridemia and hyperuricemia: effects of two fibric acid derivatives (bezafibrate and fenofibrate) in a double-blind, placebo-controlled trial.

Authors: M D Bastow; P N Durrington; M Ishola
Journal: Metabolism Date: 1988-03 Impact factor: 8.694

10. Effects of combination treatment using anti-hyperuricaemic agents with fenofibrate and/or losartan on uric acid metabolism.

Authors: S Takahashi; Y Moriwaki; T Yamamoto; Z Tsutsumi; T Ka; M Fukuchi
Journal: Ann Rheum Dis Date: 2003-06 Impact factor: 19.103

2 in total

Review 1. Serum uric acid-lowering therapies: where are we heading in management of hyperuricemia and the potential role of uricase.

Authors: John S Bomalaski; Mike A Clark
Journal: Curr Rheumatol Rep Date: 2004-06 Impact factor: 4.592

2. Fifteen years of losartan: what have we learned about losartan that can benefit chronic kidney disease patients?

Authors: Elizabeth Ripley; Ari Hirsch
Journal: Int J Nephrol Renovasc Dis Date: 2010-06-28

2 in total